Omeros Co. (NASDAQ:OMER - Get Free Report) shares passed above its 200-day moving average during trading on Tuesday . The stock has a 200-day moving average of $4.01 and traded as high as $4.43. Omeros shares last traded at $4.40, with a volume of 311,891 shares.
Analysts Set New Price Targets
Separately, StockNews.com raised Omeros from a "sell" rating to a "hold" rating in a research report on Friday, August 16th.
Check Out Our Latest Research Report on OMER
Omeros Stock Up 3.4 %
The stock's 50 day moving average price is $4.00 and its 200-day moving average price is $4.01. The stock has a market capitalization of $263.67 million, a P/E ratio of -1.94 and a beta of 1.47.
Omeros (NASDAQ:OMER - Get Free Report) last posted its quarterly earnings results on Wednesday, August 7th. The biopharmaceutical company reported ($1.12) earnings per share for the quarter. Analysts anticipate that Omeros Co. will post -2.9 earnings per share for the current year.
Institutional Trading of Omeros
A number of large investors have recently bought and sold shares of the business. BNP Paribas Financial Markets grew its holdings in Omeros by 75.5% in the first quarter. BNP Paribas Financial Markets now owns 30,102 shares of the biopharmaceutical company's stock valued at $104,000 after purchasing an additional 12,951 shares during the period. Oppenheimer & Co. Inc. purchased a new stake in Omeros during the first quarter valued at about $85,000. Susquehanna Fundamental Investments LLC acquired a new position in Omeros in the first quarter worth approximately $538,000. Vanguard Group Inc. grew its holdings in Omeros by 2.6% during the first quarter. Vanguard Group Inc. now owns 3,250,284 shares of the biopharmaceutical company's stock valued at $11,213,000 after purchasing an additional 81,348 shares during the last quarter. Finally, Comerica Bank boosted its position in shares of Omeros by 20.0% in the first quarter. Comerica Bank now owns 30,000 shares of the biopharmaceutical company's stock valued at $104,000 after acquiring an additional 5,000 shares during the period. Institutional investors and hedge funds own 48.79% of the company's stock.
Omeros Company Profile
(
Get Free Report)
Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases, including complement-mediated diseases, cancers, and addictive and compulsive disorders. The company's products under development include Narsoplimab (OMS721/MASP-2) that has completed pivotal trial for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); that is in Phase III clinical trial for the treatment of immunoglobulin A nephropathy (IgAN); and Phase II clinical trial to treat COVID-19.
Further Reading
Before you consider Omeros, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Omeros wasn't on the list.
While Omeros currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat's analysts have just released their top five short plays for December 2024. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
